FIT Biotech announced today it has signed an agreement with BD Technologies, a unit of BD (Becton, Dickinson and Company), to collaborate for the development and delivery of HIV vaccines. The parties initiated a Phase I/II multi-center clinical trial combining FIT Biotech´s GTU®-MultiHIV vaccine with BD’s disposable intradermal delivery device earlier this year. This clinical trial is part of FIT Biotech’s collaborative clinical program to develop a vaccine against HIV.

 "As a leader in drug delivery, BD is pleased to participate with FIT Biotech on new initiatives to eliminate HIV, a significant worldwide health issue. We are optimistic that our advanced drug delivery technologies, in combination with the FIT vaccine, might provide medical benefit and important advances in the field," stated Dr. Charles Goldstein, VP Research and Director of BD Technologies. 

“FIT Biotech’s HIV vaccine is based on the use of our promising DNA vector, which is capable of inducing a strong cell-mediated immune response, together with an artificial immunogen expressing most of the HIV proteins. We believe the combination of our vaccine with BD’s immune system targeted delivery device will be able to induce protective as well as therapeutic responses,” explained Prof. Kai Krohn, Senior VP and Chief Scientific Officer of FIT Biotech.